CL

Business profile & competitive position

Colgate-Palmolive Company is classified in the Consumer Defensive sector, specifically the Household & Personal Products industry. The company operates through two reportable segments: Oral, Personal and Home Care, which includes toothpaste, toothbrushes, soaps, deodorants, skin health products, household cleaners and fabric conditioners; and Hill’s Pet Nutrition, which produces specialty dog and cat foods. Its geographic footprint is genuinely global, with products marketed in more than 200 countries and territories through retailers, wholesalers, eCommerce platforms, veterinarians and select direct-to-consumer channels.

The 10-K excerpt indicates that 2025 worldwide net sales were split as follows: Oral Care 44%, Pet Nutrition 23%, Personal Care 17% and Home Care 16%. Walmart and its affiliates accounted for approximately 11% of 2025 net sales, and no other customer exceeded 10%. As of December 31, 2025, Colgate-Palmolive had approximately 33,600 employees across more than 100 countries, with over 84% of that workforce located outside the United States.

Against that operating backdrop, the company’s current net margin of 9.7% is reasonable for a branded consumer staples portfolio, but it is not the kind of supernormal margin that alone signals a wide moat. The reported return on equity of 631.1% is far elevated versus the company’s operating returns, which typically reflects a compressed or negative equity base from leveraged capital management rather than pure earnings power. Investors should therefore read the 631.1% ROE as a balance-sheet efficiency signal, not as evidence that the business earns six hundred percent incremental returns on its underlying assets. The more durable competitive claims that the data supports are global brand reach, distribution scale, science-based innovation, an agile supply chain and omni-channel demand generation.

Financial posture

Colgate-Palmolive currently carries a market capitalization of $68.1 billion and trades at a price-to-earnings ratio of 33.4. The net margin sits at 9.7%, while the beta is a low 0.32, consistent with a defensive, low-volatility consumer staples profile. At the time the data was generated, the stock price was $85.07, the RSI was 39.0 and the 50-day exponential moving average was $88.39, meaning the stock was resting slightly below that short-term moving average.

A P/E of 33.4 typically embeds expectations of stable cash flows, dividend reliability and modest growth, all of which are common hallmarks of large-cap defensive names. However, the same multiple leaves the stock vulnerable to any softness in growth or margin trajectory. The 9.7% net margin is the better metric to watch for operating health, while the 631.1% ROE is better understood as a function of capital structure than as a clean profitability score. The company explicitly lists using the balance sheet efficiently and growing free cash flow among its operational goals, so the leverage component of that ROE is not accidental.

Strategic priorities & outlook

The company’s most recent SEC 10-K filing outlines several clear priorities. Colgate-Palmolive aims to drive organic sales growth and deliver consistent, compounded earnings-per-share growth. It also targets operational efficiencies while growing free cash flow and using the balance sheet efficiently. Supporting those goals, the company emphasizes leveraging its global brand reach, science-based innovation, an agile supply chain and what it describes as best-in-class omni-channel demand generation. It is also investing in data, analytics and artificial intelligence capabilities, alongside efforts to evolve what it calls a high-impact, inclusive culture.

These priorities map cleanly onto both segments. Oral Care’s 44% revenue weight means toothpaste and toothbrushes remain the core cash engine, while Hill’s Pet Nutrition at 23% is the higher-growth, higher-margin adjacent category. The 11% customer concentration at Walmart underscores why omni-channel execution and global retail partnership management matter: the company cannot afford meaningful execution gaps with its largest channel. With the vast majority of employees outside the United States, the filing also highlights why international supply-chain and go-to-market performance are central to the outlook.

Macro & geopolitical exposure

Because Colgate-Palmolive sits in Household & Personal Products, its macro exposure is shaped by the staples playbook rather than cyclical demand swings. Demand for toothpaste, soap, pet food and household cleaners is non-discretionary, but margins can still be compressed by raw-material and packaging costs such as plastics resins, surfactants, pet-food proteins, freight and energy. With operations spanning more than 200 countries and over 84% of the workforce overseas, foreign-exchange translation is a persistent factor in both revenue and earnings.

Trade policy and tariffs also matter: many personal-care products and their inputs cross borders during manufacturing and packaging, and changes in tariffs can alter sourcing economics. Regulatory exposure is likewise material spanning the U.S. Food and Drug Administration, Federal Trade Commission, state-level ingredient laws, European REACH-style chemical regimes and pet-food labeling rules in multiple jurisdictions. Supply-chain resilience, pricing power and the ability to pass through cost increases matter more for this industry than volume volatility. The company’s low 0.32 beta confirms that equity-market sensitivity is muted, but that does not eliminate cost-side and currency-side risks.

Recent developments

Recent headlines reflect the kind of investor conversation that typically surrounds a mature defensive payer. On September 28, 2026, zacks.com asked “EYE or CL: Which Is the Better Value Stock Right Now?,” casting Colgate-Palmolive into a direct valuation comparison with another name. On September 29, 2026, fool.com published “I’d Put $1,000 Into Each of These 3 Dividend Stocks and Lose the Password,” suggesting that some dividend-focused authors continue to group Colgate-Palmolive with long-term income-oriented holdings. On September 30, 2026, zacks.com followed with “Colgate’s Innovation and Premiumization Drive: Can Momentum Persist?,” signaling particular attention to whether new product innovation and higher-priced mix can keep the sales trend moving.

On October 3, 2026, 247wallst.com ran a piece about Ronald Read, a Vermont gas station attendant who built a roughly $8 million blue-chip dividend portfolio over five decades. The article is a reminder of the long-term dividend-compounding narrative often tied to defensive consumer names, though the headline does not single out Colgate-Palmolive as a specific holding. Taken together, the coverage cluster centers on three themes: valuation relative to peers, the sustainability of innovation and premiumization, and the stock’s place in a dividend-focused portfolio.

Earnings behavior & post-earnings drift

Colgate-Palmolive has delivered an unblemished earnings record over the last eight reported quarters, posting a beat rate of 8 for 8, equal to 100%, with an average surprise of 3.3%. The average 5-day price move in the five trading days after earnings across those quarters was +2.32%, and the drift direction is classified as “up.”

The four most recent quarters illustrate that pattern with some nuance. On July 31, 2026, the company reported EPS of $0.99 against an estimate of $0.947, a 4.5% beat; the stock fell 1.56% the next day but gained 2.16% over the following five days. On May 1, 2026, EPS came in at $0.97 versus $0.943, a 2.9% beat, with the next-day reaction down 2.17% and the five-day drift up just 0.33%. On January 30, 2026, EPS of $0.95 beat the $0.912 estimate by 4.2%, pushing the stock up 1.77% the next day and up 4.56% over five sessions. On October 31, 2025, EPS was $0.91 versus $0.889, a 2.4% beat, followed by a -2.69% next-day move and a +2.22% five-day drift.

The pattern is consistent: the unofficial consensus or the market’s real expectation may run ahead of the published analyst estimate, so reported beats are not always rewarded immediately. In three of the last four quarters, the next-day reaction was negative despite the beat, only for the five-day drift to turn positive. Traders watching earnings season should note the next report is scheduled for October 30, 2026, before the market open, with a consensus EPS estimate of $0.93. At current levels the RSI is 39.0 and the price is slightly under the 50-day EMA of $88.39, adding technical context but not altering the fundamental earnings picture.

For a deeper dive into institutional conviction, valuation models and the full risk summary, review the complete institutional verdict on CL.